Skip to main navigation
About us
Our Approach
Our Pipeline
Patients
Investors
Careers
About us
Our Approach
Our Pipeline
Patients
Investors
Careers
Overview
Corporate Presentation
Overview
News & Events
News Releases
Events
Stock Information
Stock Quote & Chart
Analyst Coverage
Corporate Governance
Governance Overview
Board of Directors
Leadership
Financial Information
SEC Filings
SEC Filings - AGLE
Quarterly Results
IR Resources
Investor FAQs
Email Alerts
Contact IR

Quarterly Results

Show all

2025

Q4

  • Earnings Release 436.9 KB
  • Form 10-K 3.2 MB

Q3

  • Earnings Release 439.1 KB
  • 10-Q Filing 747.3 KB

Q2

  • Earnings Release 451.1 KB
  • 10-Q Filing 863.7 KB

Q1

  • Earnings Release 378.4 KB
  • 10-Q Filing 3 MB

2024

Q4

  • Earnings Release 403 KB
  • 10-K Filing 3 MB

Q3

  • Earnings Release 189.9 KB
  • 10-Q Filing 1.1 MB

Q2

  • Earnings Release 50.9 KB
  • 10-Q Filing 2.3 MB

Q1

  • Earnings Release 46.9 KB
  • 10-Q Filing 1.1 MB

2023

Q4

  • Earnings Release 51.2 KB
  • 10-K Filing 2.3 MB

Q3

  • Earnings Release 47.3 KB
  • 10-Q Filing 944 KB

Q2

  • Earnings Release 362 KB
  • 10-Q Filing 2.4 MB

Q1

  • Earnings Release 358.2 KB
  • 10-Q Filing 507.9 KB
  • Our Approach
  • Approach
  • Therapeutic Targets
  • Half-life Extension
  • Rational Combinations
  • Publications
  • Our Programs
  • Pipeline
  • Programs
  • Investors
  • Corporate Presentation
  • Overview
  • News & Events
  • Stock Information
  • Financial Information
  • Corporate Governance
  • IR Resources
  • Patients
  • Spyre Commitment
  • Clinical Trials & Disease Ed
  • Careers
  • Values
  • Benefits
  • Careers
  • About Us
  • People
  • Contact
Subscribe
to stay updated
  • Terms of Service
  • Privacy Policy
© 2026 Spyre Therapeutics. All rights reserved. For U.S. residents only.
Design and development by Visual Science